Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.

Shuohan Huang,Zihan Guo,Mengmeng Wang,Youjun She,Xuan Ye,Qing Zhai,Jiyong Liu,Qiong Du

Expert opinion on drug safety（2023）

引用 2|浏览11

暂无评分

摘要

Our findings support an association between several oAEs and BRAF and MEK inhibitor combination therapies, including several new oAEs. In addition, oAEs profiles may vary across the treatment regimens. Further studies are needed to better quantify these oAEs.

查看译文

关键词

Adverse event reporting system,BRAF and MEK inhibitor combination therapy,disproportionality analysis,ocular adverse events,pharmacovigilance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要